ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was upgraded by equities research analysts at TheStreet from a “c+” rating to a “b” rating in a research report issued on Thursday.
Several other brokerages have also weighed in on ANIP. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Canaccord Genuity restated a “buy” rating and issued a $66.00 price objective (up previously from $60.00) on shares of ANI Pharmaceuticals in a report on Monday, October 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Tuesday, November 7th. Finally, BidaskClub upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.25.
ANI Pharmaceuticals (NASDAQ ANIP) traded up $0.81 during trading hours on Thursday, hitting $63.75. The stock had a trading volume of 59,886 shares, compared to its average volume of 133,243. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $65.81. The company has a market capitalization of $723.15, a PE ratio of 19.12 and a beta of 2.84. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45.
TRADEMARK VIOLATION WARNING: “TheStreet Upgrades ANI Pharmaceuticals, Inc. (ANIP) to B” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/11/18/thestreet-upgrades-ani-pharmaceuticals-inc-anip-to-b.html.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA lifted its stake in ANI Pharmaceuticals by 44.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 664 shares in the last quarter. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the 3rd quarter worth about $197,000. Violich Capital Management Inc. purchased a new stake in ANI Pharmaceuticals in the 3rd quarter worth about $217,000. Municipal Employees Retirement System of Michigan lifted its stake in ANI Pharmaceuticals by 132.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after acquiring an additional 2,390 shares in the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new stake in ANI Pharmaceuticals in the 3rd quarter worth about $226,000. 56.48% of the stock is owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.